Evidence map›Paper›PMID 32884537›Full record

ArticleCase reports in oncology

Baseline Plasma EGFR Circulating Tumour DNA Levels in a Pilot Cohort of EGFR-Mutant Limited-Stage Lung Adenocarcinoma Patients Undergoing Radical Lung Radiotherapy.

Brendan Seng Hup Chia, Wen Long Nei, Sabanayagam Charumathi, Kam Weng Fong, Min-Han Tan

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Case reports in oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 53% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Brendan Seng Hup ChiaDivision of Radiation Oncology, National Cancer Centre Singapore, Singapore, Singapore.
Wen Long NeiDivision of Radiation Oncology, National Cancer Centre Singapore, Singapore, Singapore.
Sabanayagam CharumathiCentre for Quantitative Medicine, Duke-NUS Medical School, Singapore, Singapore.
Kam Weng FongDivision of Radiation Oncology, National Cancer Centre Singapore, Singapore, Singapore.
Min-Han TanInstitute of Bioengineering and Nanotechnology, ASTAR Singapore, Singapore, Singapore.
National Cancer Centre Singapore · SGDuke-NUS Medical School · SGInstitute of Bioengineering and Nanotechnology · SG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The use of circulating cell-free tumour DNA (ctDNA) is established in metastatic lung adenocarcinoma to detect and monitor sensitising EGFR mutations. In early-stage disease, there is very little data supporting its role as a potential biomarker. We report on a prospective cohort of 9 limited-stage EGFR mutant lung cancer patients who were treated with radical radiotherapy. We looked at baseline plasma EGFR ctDNA and noted the detection rates to be higher in locally advanced disease. At a median follow-up of 13.5 months, an association between a detectable pre-radiotherapy plasma EGFR ctDNA and early tumour relapse (155 days vs. NR,

Indexed as

BiomarkerCirculating tumour DNALung adenocarcinomaPlasma EGFRPrognosis

Identifiers

PMID32884537
PMCPMC7443655
OpenAlexW3045906933

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.